Drug Profile
Oncolysin B
Alternative Names: Anti-B4-bR; Anti-CD19-bR; B4 blocked ricinLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Developer ImmunoGen; Massachusetts General Hospital; Nonindustrial source
- Class Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action CD19 antigen inhibitors; Immunosuppressants; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Leukaemia; Lymphoma; Non-Hodgkin's lymphoma